Commodity Channel Index
Previous Close | 2.3600 |
Open | 2.3500 |
Bid | 2.3500 x 3000 |
Ask | 2.4400 x 3200 |
Day's Range | 2.2950 - 2.4200 |
52 Week Range | 1.9500 - 8.8200 |
Volume | |
Avg. Volume | 694,416 |
Market Cap | 206.526M |
Beta (5Y Monthly) | 0.23 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3800 |
Earnings Date | Aug 09, 2023 - Aug 14, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.40 |
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company's President of Gene Therapy, Brent Warner, will participate in a virtual fireside chat at the Stifel 2023 Tailoring Genes: Genetic Medicines Day on Tuesday, May 30, 2023 at 12:00pm PT | 03:00pm ET.
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that two abstracts have been accepted for presentation at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), being held in Montreal, Canada and virtually on June 24-28, 2023.
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today highlights its two oral and four poster presentations on the Company's preclinical gene therapy programs and platforms at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting, being held at the Los Angeles Convention Center in Los Angeles and virtually May 16 – 20, 2023.
Poseida Therapeutics ( NASDAQ:PSTX ) First Quarter 2023 Results Key Financial Results Revenue: US$10.3m (up by US$8.91m...
Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -12.50% and 3.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the first quarter ended March 31, 2023.
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that six data presentations, including two oral presentations, highlighting the Company's preclinical gene therapy programs and platforms will be presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, being held at the Los Angeles Convention Center in Los Angeles and virtually on
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that it will participate in the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 at 3:15pm PT | 6:15pm ET in Las Vegas.
To the annoyance of some shareholders, Poseida Therapeutics, Inc. ( NASDAQ:PSTX ) shares are down a considerable 44% in...
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Rafael G. Amado, M.D., to its Board of Directors, effective today.
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Compensation Committee of its Board of Directors granted an inducement award to Kristin Yarema, the Company's new President, Cell Therapy. This grant is made pursuant to the Company's 2022 Inducement Plan as an inducement material to Ms. Yarema entering into employment with the Company in accordance with
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that Kristin Yarema, Ph.D., has joined the Company as President, Cell Therapy effective today.
Key Insights Given the large stake in the stock by institutions, Poseida Therapeutics' stock price might be vulnerable...
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -182.98% and 71.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the fourth quarter and full year ended December 31, 2022.
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of five new members to its Gene Therapy Scientific Advisory Board (SAB). These world-class researchers will join George M. Church, Ph.D., Chair of Poseida's recently formed Gene Therapy SAB, to provide counsel on the Company's gene therapy programs in development.
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day to be held today at 10:00am ET / 7:00am PT.
Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...
Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company's Chief Executive Officer, Mark Gergen, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 11:00 AM ET.
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company will host a virtual R&D Day at 10:00 am - 1:30 pm ET / 7:00 - 10:30 am PT on Wednesday, February 22, 2023.
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that Eric Ostertag, M.D., Ph.D., has resigned as Executive Chairman and will retire from the Board of Directors effective February 3, 2023. However, Dr. Ostertag will continue as a consultant to the Company to advise on technical and scientific matters.
Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Luke Lango’s PSTX trade takes off … what went into the recommendation? … analyzing a trade that could be on the verge of a blast-off … are you willing to follow price-action exclusively? Let’s begin with the chart of a biotech company called Poseida Therapeutics (PSTX).As you look at this 30-month chart, what do you see?Specifically, as of late-November last year, was it a good time to enter a bullish trade on Poseida? Source: StockCharts.com Hold onto your answer for a moment. We’ll circle back